logo
Plus   Neg
Share
Email

BTG FY Product Sales At Upper End Of Its Prior Outlook - Quick Facts

BTG plc (BTG.L) issued an update for the 12 months ended 31 March 2019, revealing product sales at the top end of the Board's view. Oncology and Vascular sales are in line with the Board's projected growth range of 15-17%. Pharmaceuticals recorded double-digit growth, ahead of the company's outlook of low single digit growth. Licensing revenues are broadly flat with previous year, the Group said.

BTG plc said its Board continues to expect that the acquisition of BTG by Boston Scientific unit, which remains subject to the satisfaction or waiver of certain conditions, to close around the middle of the calendar year 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Morgan Stanley has cut its worst-case forecast on Tesla Inc.'s share price from the previous estimate of $97 to just $10, dealing another blow to the luxury electric car maker. The worst-case or "bear case" scenario by Morgan Stanley analysts takes into account the risk posed if Tesla misses its current sales outlook for China by about half. Snap Inc. on Monday announced the promotion of two executives as the company restructures its management team. The parent company of messaging app Snapchat said it has appointed Derek Andersen, currently its vice president of finance, as chief financial officer. The company also named interim CFO Lara Sweet as its first chief people officer. Both appointments are effective immediately. Nike Inc., Adidas AG and other footwear companies have urged U.S. President Donald Trump to reconsider his proposed tariffs on shoes imported from China, noting that any increase in the cost of importing shoes has a direct impact on the American footwear consumer. In a letter, more than 170 footwear companies have urged the President to immediately remove footwear from the proposed tariffs.
Follow RTT